目的 通過對天津市安定醫(yī)院2021—2023年第二類精神藥品的使用情況進行分析，為臨床上加強精神藥品管理、合理用藥提供參考。方法 通過提取2021年1月—2023年12月天津市安定醫(yī)院第二類精神藥品的相關(guān)信息，對其銷售金額、銷售量、藥物使用頻度（DDDs）、藥物日均費用（DDC）、藥物排序比（B/A）進行回顧性統(tǒng)計分析。結(jié)果 天津市安定醫(yī)院第二類精神藥品銷售金額和DDDs逐年增長，艾司唑侖片的DDDs始終位于第1位；第二類精神藥品的DDC值總體上較為穩(wěn)定，個別品種出現(xiàn)上漲。奧沙西泮片、扎來普隆片、咪達唑侖片的DDC值排序始終位于前3位；艾司唑侖片、阿普唑侖片等藥物的B/A大于1，地西泮注射液、地西泮片的B/A接近于1，咪達唑侖片、扎來普隆片、酒石酸唑吡坦片等藥物的B/A小于1，咪達唑侖注射液的B/A等于1。結(jié)論 天津市安定醫(yī)院第二類精神藥品的使用基本合理，建議以國家三級公立醫(yī)院績效考核為抓手，多措并舉優(yōu)化各項藥事管理措施，進一步提升合理用藥的精細化管理水平。

Objective To analyze the use of second type of psychotropic drugs in Tianjin Anding Hospital from 2021 to 2023, and provide reference for strengthening the management of psychotropic drugs and rational drug use in clinical practice. Method By extracting relevant information on second type of psychotropic drugs from Tianjin Anding Hospital from January 2021 to December 2023, a retrospective statistical analysis was conducted on their sales amount, sales volume, DDDs, DDC, and B/A. Results The consumption sum and DDDs of the second type of psychotropic drugs in Tianjin Anding Hospital increased year by year, and the DDDs of Estazolam Tablets always ranked first. The DDC value of the second type of psychotropic drugs was generally stable, and some varieties showed an increase. The DDC values of Oxazepam Tablets, Zaleplon Tablets, and Midazolam Tablets were always ranked in the top 3. The B/A of Estazolam Tablets, Alprazolam Tablets, and other drugs is greater than 1, that of Diazepam Injection and DiazepamTablets is close to 1, that of Midazolam Tablets, Zaleplon Tablets, Zolpidem Tartrate Tablets and other drugs is less than 1, that of Midazolam Injection is equal to 1. Conclusion The use of second type of psychotropic drugs in Tianjin Anding Hospital is basically reasonable. It is recommended to use the performance evaluation of national tertiary public hospitals as a starting point, take multiple measures to optimize various pharmaceutical management measures, and improve the level of refined management of rational drug use.

R971

天津醫(yī)科大學(xué)醫(yī)院管理創(chuàng)新研究項目資助（2022YG24）